Informazioni sul prodotto
Nome:
Tafamidis meglumine
Sinonimi:
- Vyndaqel
- Fx 1006A
- D-Glucitol, 1-deoxy-1-(methylamino)-, 2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate (1:1)
Descrizione:
Tafamidis meglumine is a drug that belongs to the class of drugs for treating cardiomyopathy. It is a prodrug of tafamidis which is hydrolyzed in vivo to its active form, tafamidis meglumine. Tafamidis meglumine has long-term efficacy and prevents the progression of heart failure by inhibiting the development of cardiac hypertrophy. This drug also has been shown to be effective against brain natriuretic peptides and other symptoms such as edema, anemia, and renal dysfunction. Tafamidis meglumine inhibits the activity of protein phosphatase 2A (PP2A), which dephosphorylates cardiac troponin I at serine residue 222. This leads to increased levels of troponin I, which induces apoptosis in cardiomyocytes.
Avviso:
I nostri prodotti sono destinati esclusivamente ad uso di laboratorio. Per qualsiasi altro utilizzo, vi preghiamo di contattarci.
Marchio:
Biosynth
Conservazione lunga:
Note:
Proprietà chimiche
Peso molecolare:
503.33 g/mol
Formula:
C21H24Cl2N2O8
Purezza:
Min. 95%
MDL:
Punto di fusione:
Punto di ebollizione:
Punto di infiammabilità:
Densità:
Concentrazione:
EINECS:
Merck:
Codice SA:
